Will DOW disclose a Sadara JV impairment charge before December 31, 2026?
Current Prediction
Why This Question Matters
Sadara is the single largest unquantified contingent exposure in the dossier. Equity-method losses jumped 40x to $(240)M in FY25. DOW announced a strategic review for 2026. A disclosed impairment would crystallize an exposure that all seven lenses treated as latent, materially impacting GAAP results and potentially triggering debt-guarantee scrutiny. Black Swan Beacon assigns 15-25% probability to an impairment event. Resolution would either confirm the tail or validate the committee's latent-exposure assumption.
Prediction Distribution
Individual Predictions(9 runs)
Black Swan Beacon assigns 15-25% probability. I lean toward the upper end because: (1) equity-method losses jumped 40x to $(240)M in FY25 — this trajectory typically precedes explicit impairment within 12 months, (2) strategic review was announced for 2026, which creates forcing function, (3) quarterly audit testing gives 3 additional chances to trigger impairment disclosure before year-end. Strategic reviews of this type typically conclude with disclosure 60-75% of the time. ~30%.
Committee range 15-25% anchors at upper end. Strategic review could extend into 2027 (mgmt has incentive to delay bad news) — this cuts probability. Offsetting: equity-method losses widening quarterly creates mechanical impairment triggers via below-the-line charges even absent formal strategic review conclusion. Balance: ~25%.
Strategic reviews of large JVs announced for a specific year conclude with disclosure approximately 65% of the time. Disclosures break down into: full impairment (~25% of outcomes), partial (~30%), restructure without impairment (~25%), silent continuation (~20%). Question resolves YES on any accounting impairment. Combining strategic review conclusion probability with disclosure split: ~25-30%.
Committee 15-25%. Mid-point 20% with slight upward adjustment for equity-method loss trajectory (40x increase is acute signal). ~25%.
Saudi JV impairments specifically have 12-24 month typical resolution windows from first trigger signals. FY25 40x loss is a trigger signal. 2026-12-31 captures one year from trigger — at lower end of typical resolution window. ~22%.
Strategic review announcement for 2026 is the key. Management typically concludes strategic reviews to avoid extending uncertainty — 6-12 month typical conclusion. Mid-2026 conclusion implies disclosure in Q3/Q4 2026 earnings. Probability of impairment disclosure conditional on review conclusion: ~50%. Combined: ~28%.
Black Swan 15-25%. Equity-method losses accelerating. Strategic review 2026. ~25%.
Committee upper end 25%. Strategic review forcing function. Quarterly audit tests. ~25%.
Committee midpoint 20%. Management may delay review conclusion into 2027. ~22%.
Resolution Criteria
Resolves YES if DOW discloses a goodwill, asset, or equity-method impairment charge specifically related to the Sadara JV in any quarterly earnings release, 10-Q, 10-K, or 8-K before 2026-12-31. Also resolves YES if DOW announces a Sadara equity injection, debt guarantee crystallization, or ownership restructuring that triggers an accounting impairment. Resolves NO if no such disclosure occurs by 2026-12-31.
Resolution Source
DOW 10-Q, 10-K, 8-K filings, earnings releases, and strategic review announcements
Source Trigger
Sadara JV impairment disclosed before 2026-12-31
Full multi-lens equity analysis